More than 96% of urologists surveyed said that incorporating abiraterone acetate (ZYTIGA) treatment into practice for patients with metastatic castrate-resistant prostate cancer is easy or manageable after overcoming initial barriers, according to new research presented at the Genitourinary Cancers Symposium in Orlando, FL.
Lead author Andrew Feifer, MD, staff uro-oncologist at Trillium Health Partners and associate staff at University Health Network, Toronto, told Urology Times that he and his co-authors set out to better understand whether urologists’ real-world interpretations of incorporating abiraterone acetate into practice mimicked the positive data coming out of two phase III trials on the drug’s use in metastatic castration-resistant prostate cancer.
Abiraterone has been shown to increase overall survival and improve quality of life. In one phase III study, patients with metastatic castration-resistant prostate cancer who were treated with abiraterone and prednisone had a mean 8.2-month longer overall survival compared to patients who received prednisone only (N Engl J Med 2013; 368:138-48). The abiraterone-prednisone group also had a longer time to initiation of cytotoxic chemotherapy, lower opiate use for cancer-related pain, improved PSA progression, and less decline in performance status, according to the study.
In the current study, the authors developed a questionnaire to assess academic and community urologists’ experiences with integrating the oral antiandrogen therapy into practice. Their study reflects responses from 30 sites in Canada, of which 93.3% of providers responding were urologists. Sixty-three percent of the urologists responding were in the community setting, versus 30% in academic practice.
“What we found was that roughly 50% of urologists involved were very comfortable with administering the medication to their patients,” Dr. Feifer said. “[Another] 46.7% had really no significant concerns, and 3.3% thought there were really tremendous barriers to implementation.”